Safety of allergen immunotherapy: A review of premedication and dose adjustment

Immunotherapy

Volumn 4, Issue 3, 2012, Pages 315-322

  Morris, A Erika ^a   Marshall, Gailen D ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

dose adjustment; immunotherapy; inhalant allergen; subcutaneous immunotherapy; venom immunotherapy

Indexed keywords

ADRENALIN; ALLERGEN; ANTIHISTAMINIC AGENT; CORTICOSTEROID; DESLORATADINE; FEXOFENADINE; GLYCEROL; HYMENOPTERA VENOM; IMMUNOGLOBULIN E ANTIBODY; IMMUNOMODULATING AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LORATADINE; MONTELUKAST; PLACEBO; PREDNISONE; RANITIDINE; TERFENADINE;

ALLERGIC ASTHMA; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; APOPTOSIS; BODY TEMPERATURE DISORDER; CHEST TIGHTNESS; CLONAL ANERGY; CONTROLLED CLINICAL TRIAL (TOPIC); DELAYED HYPERSENSITIVITY; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SENSITIZATION; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; HUMAN; HYMENOPTERA; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INJECTION SITE PAIN; INSECT ALLERGY; MAINTENANCE DRUG DOSE; MULTICENTER STUDY (TOPIC); NAUSEA; PATIENT COMPLIANCE; POLLEN ALLERGY; PREMEDICATION; PRIORITY JOURNAL; PRURITUS; RAGWEED POLLEN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN ALLERGY; SKIN REDNESS; SUBCUTANEOUS IMMUNOTHERAPY; SWELLING; TACHYCARDIA; TREATMENT REFUSAL; URTICARIA;

ALLERGENS; ANAPHYLAXIS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY; RISK FACTORS; SAFETY;

EID: 84858300814     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.4     Document Type: Review

References (27)

1. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J. Allergy Clin. Immunol. 127(1 Suppl.), S1-S55 (2011).
2. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J. Allergy Clin. Immunol. 113(6), 1025-1034 (2004). (Pubitemid 38857978)
3. Nelson HS. Efficacy and safety of allergen immunotherapy in children. Ann. Allergy Asthma Immunol. 96(Suppl. 1), S2-S5 (2006). (Pubitemid 43287650)
4. Webber CM, Calabria CW. Assessing the safety of subcutaneous immunotherapy dose adjustments. Ann. Allergy Asthma Immunol. 105, 369-375 (2010).
5. Calabria CW, Stolfi A, Tankersley MS. The REPEAT study: recognizing and evaluating periodic local reactions in allergen immunotherapy and associated systemic reactions. Ann. Allergy Asthma Immunol. 106, 49-53 (2011).
6. Calabria CW, Coop CA, Tankersley MS. The GILL study: glycerin induced local reactions in immunotherapy. J. Allergy Clin. Immunol. 121, 222-226 (2008).
7. Tankersley MS, Butler KK, Butler WK, Goetz DW. Local reactions during allergen immunotherapy do not require dose adjustment. J. Allergy Clin. Immunol. 106, 840-843 (2000).
8. Calabria CW, Coop CA, Tankersley MS. The LOCAL study: local reactions do not predict local reactions in allergen immunotherapy. J. Allergy Clin. Immunol. 124, 739-744 (2009).
9. Roy SR, Sigmon JR, Olivier J, Moffitt JE, Brown DA, Marshall GD. Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy. Ann. Allergy Asthma Immunol. 99, 82-86 (2007). (Pubitemid 47075956)
10. Kelso JM. The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. Ann. Allergy Asthma Immunol. 92, 225-227 (2004). (Pubitemid 38233660)
11. Nielson L, Johnsen C, Mosbech H, Poulsen L, Malling HJ. Antihistamine pre-medication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J. Allergy Clin. Immunol. 97, 1207-1213 (1996).
12. Reimers A, Hari Y, Muller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy 55, 484-488 (2000). (Pubitemid 30230359)
13. Wohrl S, Gamper S, Hemmer W, Heinze G, Stingl G, Kinaciyan T. Premedication with montelukast reduces local reactions of allergen immunotherapy. Int. Arch. Allergy Immunol. 144, 137-142 (2007). (Pubitemid 47414328)
14. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: the World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J. Allergy Clin. Immunol. 125, 569-574 (2010).
15. Bernstein DI, Wanner M, Borish L, Liss GM; Immunotherapy Committee of the American Academy of Allergy, Asthma and Immunology. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J. Allergy Clin. Immunol. 113(6), 1129-1136 (2004). (Pubitemid 38857996)
16. Ohashi Y, Nakai Y, Murata K. Effect of pretreatment with fexofenadine on the safety of immunotherapy in patients with allergic rhinitis. Ann. Allergy Asthma Immunol. 96, 600-605 (2006).
17. Portnoy J, Bagstad K, Kanarek H, Pacheco F, Hall B, Barnes C. Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts. Ann. Allergy 73, 409-418 (1994). (Pubitemid 24368195)
18. Brockow K, Kiehn M, Riethmuller C, Vieluf D, Berger J, Ring J. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 100, 458-463 (1997).
19. Tankersley MS, Walker RL, Butler WK, Hagan LL, Napoli DC, Freeman TM. Safety and efficacy of an imported fire ant rush immunotherapy protocol with and without prophylactic treatment. J. Allergy Clin. Immunol. 109(3), 556-62 (2002). (Pubitemid 34234210)
20. Dietrich JJ, Moore LM, Nguyen S, Hagan LL, Tankersley MS. Imported fire ant hypersensitivity: a 1-day rush immunotherapy schedule without premedication. Ann. Allergy Asthma Immunol. 103(6), 535-536 (2009).
21. Tinkelman DG, Cole WQ 3rd, Tunno J. Immunotherapy: a one-year prospective study to evaluate risk factors of systemic reactions. J. Allergy Clin. Immunol. 95, 8-14 (1995).
22. Lin MS, Tanner E, Lynn J, Friday GA Jr. Nonfatal systemic allergic reactions induced by skin testing and immunotherapy. Ann. Allergy 71, 557-562 (1993). (Pubitemid 24005750)
23. Montgomery JR. The need for standardizing the aeroallergen immunotherapy missed-dose adjustment protocol. Allergy Asthma Proc. 29, 425-426 (2008).
24. Coop CA, Tankersley MS. Dose adjustment practices among allergists for local reactions to immunotherapy. Ann. Allergy Asthma Immunol. 99, 77-81 (2007). (Pubitemid 47075955)
25. Coop CA, Tankersley MS. Patient perceptions regarding local reactions from allergen immunotherapy injections. Ann. Allergy Asthma Immunol. 101, 96-100 (2008). (Pubitemid 352000751)
26. More DR, Hagan LL. Factors affecting compliance with allergen immunotherapy at a military medical center. Ann. Allergy Asthma Immunol. 88, 391-394 (2002). (Pubitemid 34408565)
27. Cohn JR, Pizzi A. Determinants of patient compliance with allergen immunotherapy. J. Allergy Clin. Immunol. 91, 734-737 (1993). (Pubitemid 23110718)